Full View

Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X/L861Q/S768I

LL Pang, JD Gan, JR Tan, YH Huang, J Liao… - Cancer, 2022 - Wiley Online Library
Background Afatinib is the only currently approved EGFR‐tyrosine kinase inhibitors for
advanced non–small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …
被引用次数：14 相关文章

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.

LL Pang, JD Gan, JR Tan, YH Huang… - Cancer …, 2022 - search.ebscohost.com
Abstract < bold> Background: </bold> Afatinib is the only currently approved EGFR-
tyrosine kinase inhibitors for advanced non-small cell lung cancer (NSCLC) patients with …

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I

LL Pang, JD Gan, JR Tan, YH Huang, J Liao… - Cancer, 2022 - pubmed.ncbi.nlm.nih.gov
Background Afatinib is the only currently approved EGFR-tyrosine kinase inhibitors for
advanced non-small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.

LL Pang, JD Gan, JR Tan, YH Huang, J Liao, WT Liang… - Cancer, 2022 - europepmc.org
Background Afatinib is the only currently approved EGFR-tyrosine kinase inhibitors for
advanced non-small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …